Engineered microorganisms for detection of diseased cells
US-2024118283-A1 · Apr 11, 2024 · US
Methods and materials for increasing viral vector infectivity
US11207424B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11207424-B2 |
| Application number | US-201515318618-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 12, 2015 |
| Priority date | Jun 13, 2014 |
| Publication date | Dec 28, 2021 |
| Grant date | Dec 28, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This document relates to methods and materials for increasing viral vector infectivity. For example, methods and materials for using spliceosome inhibitors (e.g., U2 snRNP spliceosome inhibitors such as meayamycin B or pladienolide derivative E7107) to increase viral vector (e.g., adeno-associated virus-based vector) infectivity are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for infecting a mammal with an AAV vector, wherein said method comprises administering said AAV vector in the presence of a U2 snRNP spliceosome inhibitor to said mammal, wherein said inhibitor is administered within 12 hours preinfection and within 24 hours post-infection, wherein the dose of the AAV vector in the presence of said U2 snRNP spliceosome inhibitor is lower than the dose of said AAV vector in the absence of said U2 snRNP spliceosome inhibitor. 2. The method of claim 1 , wherein said mammal is a human. 3. The method of claim 1 , wherein said AAV vector is an AAV1, AAV2, AAV3, AAV4, or AAV5 vector. 4. The method of claim 1 , wherein said inhibitor is meayamycin B or E7107.
Assignees
Inventors
Classifications
- A61K48/0083Primary
characterised by an aspect of the administration regime · CPC title
viral genome or elements thereof as genetic vector · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
- A61K48/00Primary
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11207424B2 cover?
- This document relates to methods and materials for increasing viral vector infectivity. For example, methods and materials for using spliceosome inhibitors (e.g., U2 snRNP spliceosome inhibitors such as meayamycin B or pladienolide derivative E7107) to increase viral vector (e.g., adeno-associated virus-based vector) infectivity are provided.
- Who is the assignee on this patent?
- Mayo Found Medical Education & Res, Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education, Univ Of Pittsburgh—Of The Commonwealth System Of Higher Educat
- What technology area does this patent fall under?
- Primary CPC classification A61K48/0083. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).